Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]
SEC Accession No. 0001558370-16-007810
Filing Date
2016-08-09
Accepted
2016-08-09 16:18:49
Documents
49
Period of Report
2016-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q/A axsm-20160331x10qa.htm 10-Q/A 1264597
2 EX-31.1 axsm-20160331ex311df9ab1.htm EX-31.1 14991
3 EX-31.2 axsm-20160331ex312f60c9f.htm EX-31.2 15343
4 EX-32.1 axsm-20160331ex321acbb1f.htm EX-32.1 7922
5 EX-32.2 axsm-20160331ex322d88834.htm EX-32.2 7559
  Complete submission text file 0001558370-16-007810.txt   3506757

Data Files

Seq Description Document Type Size
6 EX-101.INS axsm-20160331.xml EX-101.INS 535945
7 EX-101.SCH axsm-20160331.xsd EX-101.SCH 23035
8 EX-101.CAL axsm-20160331_cal.xml EX-101.CAL 22217
9 EX-101.DEF axsm-20160331_def.xml EX-101.DEF 72848
10 EX-101.LAB axsm-20160331_lab.xml EX-101.LAB 253978
11 EX-101.PRE axsm-20160331_pre.xml EX-101.PRE 175169
Mailing Address 25 BROADWAY, 9TH FLOOR NEW YORK NY 10004
Business Address 25 BROADWAY, 9TH FLOOR NEW YORK NY 10004 212-203-5072
Axsome Therapeutics, Inc. (Filer) CIK: 0001579428 (see all company filings)

EIN.: 454241907 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q/A | Act: 34 | File No.: 001-37635 | Film No.: 161818179
SIC: 2834 Pharmaceutical Preparations